Quickly and confidently determine if your mCRPC patient is likely to benefit from an AR-targeted therapy.
The first and only test of its kind to identify patients who will NOT respond to AR-targeted therapies
Finding the most effective treatment for your patients with metastatic castration-resistant prostate cancer (mCRPC) can be a challenge. The Oncotype DX AR-V7 Nucleus Detect test helps you quickly and confidently determine next treatment.
Confidently guide next treatment decisions in mCRPC
Not all mCRPC patients respond to androgen receptor (AR)-targeted therapies, like abiraterone (Zytiga®)and enzalutamide (Xtandi®).1 When AR-targeted therapy fails, acquired resistance could be the cause.1 The only predictive and prognostic test for patients with mCRPC, the AR-V7 Nucleus Detect test:
- Accurately identifies patients who will not benefit from AR-targeted therapies.2-3
- Is predictive of improved overall survival with taxanes versus AR-targeted therapies.2-3
- Provides easy-to-interpret results (a positive or negative result).
The AR-V7 Nucleus Detect test provides unparalleled specificity by detecting AR-V7 proteins in the nucleus of circulating tumor cells (not cytoplasmic AR-V7 proteins). Find out more about nuclear detection.
Get fast results from a simple blood draw
The Oncotype DX AR-V7 Nucleus Detect test is a liquid biopsy assay that analyzes circulating tumor cells in a patient's blood. No intrusive or complicated procedures are required. The results are reported to the ordering physician through a secure portal, confirming the patient as either AR-V7+ or AR-V7-. Learn how to order and use the AR-V7 Nucleus Detect test.